A Pharmaceopidemiological Study in Patients Who Use Symbicort SMART

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00503061
First received: July 17, 2007
Last updated: November 30, 2010
Last verified: November 2010
  Purpose

To investigate how common it is that patients using Symibort SMART take high average daily doses that are not considered appropriate by their physician (overuse) or are hospitalised due to their asthma at least partly due to underuse.


Condition
Bronchial Asthma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pharmaceopidemiological Study in Patients Who Use Symbicort Turbuhaler as Maintenance and Reliever Therapy (Symbicort SMART) Capturing Over Use and Under Use Via the General Practice Research Database

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Enrollment: 1000
Study Start Date: June 2007
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Population comes from Primary Care Clinics and Pulmonary Experts

Criteria

Inclusion Criteria:

  • Asthma diagnosis, patient registered with the prescribing physician for at least one year before the qualifying prescription of Symbicort, prescription of Symbicort SMART after UK launch of the concept

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00503061

Locations
United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Catriona McMahon, MD AZ UK MC
Study Director: Tomas Andersson, MD AZ R&D Lund
  More Information

No publications provided

Responsible Party: Tomas Andersson, MSD, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00503061     History of Changes
Other Study ID Numbers: D5890C00017, GPRD
Study First Received: July 17, 2007
Last Updated: November 30, 2010
Health Authority: United Kingdom: Independent Scientific Advisory Committee

Keywords provided by AstraZeneca:
pharmaceopidemiological
Symbicort SMART
GPRD

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Symbicort
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014